These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 21083700)
1. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Bao YQ; Zhou M; Zhou J; Lu W; Gao YC; Pan XP; Tang JL; Lu HJ; Jia WP Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):50-4. PubMed ID: 21083700 [TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes. Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951 [TBL] [Abstract][Full Text] [Related]
3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089 [TBL] [Abstract][Full Text] [Related]
6. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943 [TBL] [Abstract][Full Text] [Related]
8. The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus. Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z J Int Med Res; 1996; 24(5):438-47. PubMed ID: 8895048 [TBL] [Abstract][Full Text] [Related]
9. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Reed J; Dong T; Eaton E; Friswold J; Porges J; Al-Kindi SG; Rajagopalan S; Neeland IJ Diabetes Obes Metab; 2024 Jul; 26(7):2881-2889. PubMed ID: 38680050 [TBL] [Abstract][Full Text] [Related]
10. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. He YL; Foteinos G; Neelakantham S; Mattapalli D; Kulmatycki K; Forst T; Taylor A Diabetes Obes Metab; 2013 Dec; 15(12):1111-9. PubMed ID: 23782529 [TBL] [Abstract][Full Text] [Related]
12. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Torekov SS; Holst JJ; Ehlers MR Diabetes Obes Metab; 2014 May; 16(5):451-6. PubMed ID: 24251641 [TBL] [Abstract][Full Text] [Related]
13. Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control. Suh S; Joung JY; Jin SM; Kim MY; Bae JC; Park HD; Lee MS; Lee MK; Kim JH Diabetes Metab; 2014 Sep; 40(4):272-7. PubMed ID: 24630733 [TBL] [Abstract][Full Text] [Related]
14. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144 [TBL] [Abstract][Full Text] [Related]
15. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study. Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC; Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220 [TBL] [Abstract][Full Text] [Related]
17. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial. Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT; Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062 [TBL] [Abstract][Full Text] [Related]
18. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). Park SE; Lee BW; Kim JH; Lee WJ; Cho JH; Jung CH; Lee SH; Suh S; Hur GC; Kim SH; Jang YH; Park CY; Diabetes Obes Metab; 2017 Jun; 19(6):892-896. PubMed ID: 28058753 [TBL] [Abstract][Full Text] [Related]
19. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. Saito N; Sakai H; Suzuki S; Sekihara H; Yajima Y J Int Med Res; 1998; 26(5):219-32. PubMed ID: 9924706 [TBL] [Abstract][Full Text] [Related]
20. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes? Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]